Literature DB >> 25892440

Establishment and characterization of GCSR1, a multi-drug resistant signet ring cell gastric cancer cell line.

Xin Xu1, Li-Juan Qian2, Xing-Yun Su1, Kui-Feng He1, Ke-Tao Jin1, Lin-Hui Gu2, Jian-Guo Feng2, Guang-Liang Li1, Quan Zhou1, Zhen-Zhen Xu1, Hao-Hao Wang1, Jing Zhang1, Jiang Cao3, Li-Song Teng1.   

Abstract

Signet ring cell gastric cancer (SRCGC) has very poor prognosis worldwide, and studying its molecular characteristics is urgent for improving the outcome. However, few well-characterized SRCGC cell lines are available for research. Therefore, we established a novel cell line GCSR1, from a Chinese male SRCGC patient. Cell morphology of GCSR1 in culture, maintained in vitro for over 90 passages, is similar to the cells from the patient. GCSR1 cells proliferated in vitro with a doubling time of 67.65 h. Karyotyping showed they were aneuploid. Missense mutation occurred in codon 193 of P53 and deletion occurred in exons 1 and 3 of P16. Results of CCK8 assay revealed that GCSR1 was more resistant to 5-fluorouracil (5-FU) and mitomycin (MMC) than other gastric cancer cell lines. Stem cell marker assay by flow cytometry showed that GCSR1 had high proportion of CD44+ and/or CD133+ cells. It formed colonies easily in soft agar and generated xenograft tumors in nude mice. In conclusion, GCSR1 is a well-established, well-characterized multi-drug resistant cell line with abundant cancer stem cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25892440     DOI: 10.3892/ijo.2015.2966

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  The keratin 17/YAP/IL6 axis contributes to E-cadherin loss and aggressiveness of diffuse gastric cancer.

Authors:  Mengjie Li; Xianping Rao; Yun Cui; Lu Zhang; Xiang Li; Boya Wang; Yijun Zheng; Lisong Teng; Tianhua Zhou; Wei Zhuo
Journal:  Oncogene       Date:  2021-11-29       Impact factor: 9.867

2.  m6Am methyltransferase PCIF1 is essential for aggressiveness of gastric cancer cells by inhibiting TM9SF1 mRNA translation.

Authors:  Wei Zhuo; Meng Sun; Kun Wang; Lu Zhang; Kai Li; Danyang Yi; Mengjie Li; Qiang Sun; Xixi Ma; Wei Liu; Lisong Teng; Chengqi Yi; Tianhua Zhou
Journal:  Cell Discov       Date:  2022-05-21       Impact factor: 38.079

3.  miR-34a mimic or pre-mir-34a, which is the better option for cancer therapy? KatoIII as a model to study miRNA action in human gastric cancer cells.

Authors:  Narjes Jafari; Saeid Abediankenari; Hadi Hossein-Nataj
Journal:  Cancer Cell Int       Date:  2021-03-19       Impact factor: 5.722

4.  lncRNA SNHG4 promotes cell proliferation, migration, invasion and the epithelial-mesenchymal transition process via sponging miR-204-5p in gastric cancer.

Authors:  Shimei Wang; Wei Zhu; Ji Qiu; Fei Chen
Journal:  Mol Med Rep       Date:  2020-11-25       Impact factor: 2.952

5.  Establishment and Characterization of a Highly Metastatic Ovarian Cancer Cell Line.

Authors:  Jiang Ruibin; Cheng Guoping; Zheng Zhiguo; Ni Maowei; Wan Danying; Feng Jianguo; Gu Linhui
Journal:  Biomed Res Int       Date:  2018-06-25       Impact factor: 3.411

6.  Synergism of rMV-Hu191 with cisplatin to treat gastric cancer by acid sphingomyelinase-mediated apoptosis requiring integrity of lipid raft microdomains.

Authors:  Yao Lv; Chu-di Zhang; Yi-Long Wang; Dong-Ming Zhou; Meng-Ying Zhu; Xiao-Qiang Hao; Jin-Hu Wang; Wei-Zhong Gu; Hong-Qiang Shen; Jin-Gan Lou; Ben-Qing Wu; Pei-Chun Chen; Zheng-Yan Zhao
Journal:  Gastric Cancer       Date:  2021-07-12       Impact factor: 7.701

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.